Joan Albanell, MD, Pompeu Fabra University, Barcelona, Spain, discusses the results from the FLIPPER trial (NCT02690480). The FLIPPER trial is a randomized Phase II study that investigated the efficacy of fulvestrant plus palbociclib vs fulvestrant plus placebo in postmenopausal women with hormone receptor positive (HR+)/HER2 negative (HER2–) endocrine-sensitive advanced breast cancer (ABC). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).